

PTO/SB/004 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/752,639
(use as many sheets as necessary)		Filing Date	December 29, 2000
Sheet	2	First Named Inventor	GATANAGA, TETSUYA
of		Group Art Unit	1646
		Examiner Name	MURPHY, JOSEPH F.
		Attorney Docket Number	IRVN-007CON2

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		Aderka et al. "Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients." Cancer Res. 51:5602, 1991.
		Aggarwal et al. "Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon." Nature 318:665, 1985.
		Baglioni et al. "Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition." J. Biol. Chem. 260:13395, 1985.
		Brakebusch et al. "Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor." EMBO J. 11:943, 1992.
		Diez-Ruiz et al. "Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis." Eur. J. Haematol. 54:1, 1995.
		Grosch et al. "Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy." Gynecol. Oncol. 50:68, 1993.
		Gullberg et al. "Involvement of an Asn/Val cleavage site in the production of a soluble form of a human tumor necrosis factor (TNF) receptor. Site-directed mutagenesis of a putative cleavage site in the p55 TNF receptor chain." Eur. J. Cell Biol. 58:307, 1992.
		Halwachs et al. "Serum levels of the soluble receptor for tumor necrosis factor in patients with renal disease." Clin. Invest. 72:473, 1994.
		Holtmann & Wallach. "Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate." J. Immunol. 139:1161, 1987.
		Kochi et al. "Characterization and affinity crosslinking of receptors for tumor necrosis factor on human cells." Arch. Biochem. Biophys. 249:263, 1986.
		Kull et al. "Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity." Proc. Natl. Acad. Sci. USA 82:5756, 1985.
		Porter et al. "Shedding of tumor necrosis factor receptors by activated human neutrophils." J. Exp. Med. 172:599, 1990.
		Rodt et al. "Tumor necrosis factor (TNF) dependent shedding of the p55 TNF receptor in a baboon model of bacteremia." Infect. Immun. 63:297, 1995
		Schall et al. "Molecular cloning and expression of a receptor for human tumor necrosis factor." [Relation between membrane TNF-R and the soluble form] Cell 61:361, 1990.
Examiner Signature	<i>[Signature]</i>	
	Date Considered	8-26-03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SD/08A (10-01)

Approved for use through 10/31/2002, OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number Filing Date First Named Inventor Group Art. Unit Examiner Name Attorney Docket Number	09/752,639 December 29, 2000 GATANAGA, JETSUYA 1646 MURPHY, JOSEPH F. IRVN-007CON2
Sheet	2	of	2

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS		
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
<i>J</i>	Yonchara et al. "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor." J. Exp. Med. 169:1747, 1989.	
<i>K</i>	Yoshie et al. "Binding and crosslinking of 125I-labeled recombinant human tumor necrosis factor to cell surface receptors. J. Biochem. (Tokyo) 100:531, 1986.	

Examiner Signature	<i>J</i>	Date Considered	8-26-03
--------------------	----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.